Proteome

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Mittwoch, März 6, 2024

BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.
  • FMC-376 was discovered by applying the Frontier™ Platform to directly engage both ON+OFF KRASG12C with exquisite selectivity.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the lack of response and resistance seen with current KRASG12C single-acting treatments.
  • For more information on the PROSPER trial, please visit clinicaltrials.gov .

Frontier Medicines to Participate in Upcoming Investor Conferences

Retrieved on: 
Dienstag, Februar 27, 2024

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Retrieved on: 
Donnerstag, Februar 22, 2024

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million Series C financing. The financing was co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.

Key Points: 
  • This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.
  • “Frontier Medicines is a leading chemoproteomics company with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach.
  • The participation in Frontier Medicines' Series C round aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world.”
    Financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376.
  • “Today we mark the first participant dosed with a therapeutic candidate born from the Frontier™ Platform, alongside a financing that affirms continued strong investor support.

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Donnerstag, März 7, 2024

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Mittwoch, März 6, 2024

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

CellarisBio launches out of stealth with robust cell target engagement platform -- empowering drug discovery for challenging targets

Retrieved on: 
Montag, Februar 26, 2024

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- CellarisBio is officially out of stealth mode with the launch of its robust Micro-Tag cell target engagement platform.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- CellarisBio is officially out of stealth mode with the launch of its robust Micro-Tag cell target engagement platform.
  • The new platform is poised to empower biotech companies involved in target-based drug discovery.
  • CellarisBio enables discovery of novel therapeutics within the native environment of the cell, without disrupting the valuable cell biology.
  • We are particularly keen on challenging drug targets, proteins that historically have been labeled as undruggable.

Hauptman-Woodward Medical Research Institute and Kemp Proteins Enter Strategic Partnership for offering "Gene to Structure" solutions

Retrieved on: 
Dienstag, Februar 20, 2024

FREDERICK, Md., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Kemp Proteins LLC, a leading provider of gene-to-protein and monoclonal antibody development services, today announced that the company has entered into a Strategic Partnership with Hauptman-Woodward Medical Research Institute (HWMRI). With a rich history in protein structural biology, HWMRI uses its experience and developments to characterize protein structure to better understand their biological function and the potential solutions for treating cancers, infectious disease, and metabolic disorders. The agreement demonstrates Kemp's commitment to building a broad complement of bioservices focused on providing biopharmaceutical and diagnostic clients with world-class protein related development services and proteins as tools in drug development.

Key Points: 
  • FREDERICK, Md., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Kemp Proteins LLC, a leading provider of gene-to-protein and monoclonal antibody development services, today announced that the company has entered into a Strategic Partnership with Hauptman-Woodward Medical Research Institute (HWMRI).
  • We are excited to work with Kemp Proteins and see a compelling synergy with the technologies and expertise that this partnership enables."
  • Kemp Proteins will produce, purify and QC the POI in its modern facility before shipping to HWMRI.
  • "We are proud to establish this partnership as few institutes have the breadth of experience and historical significance in the field."

Could protecting our proteins help us prevent ageing?

Retrieved on: 
Mittwoch, Februar 7, 2024

This is Deinococcus radiodurans, one of the most resistant bacteria known to date, which lives in arid environments such as desert sand.

Key Points: 
  • This is Deinococcus radiodurans, one of the most resistant bacteria known to date, which lives in arid environments such as desert sand.
  • It can also overcome an irradiation dose 5,000 times greater than the lethal dose for humans.
  • Its DNA isn’t resistant, it’s simply repaired immediately by proteins that are indestructible in the face of this extreme radiation.
  • Hence the secret of the robustness of this extremophilic bacterium depends on the robustness of its “proteome” – the sum of all its proteins – and in particular its DNA repair proteins.

The keys to ageing

  • Numerous models have been proposed to explain the molecular basis of ageing, such as the theory of cellular senescence, the reduction in DNA repair capacity, telomere shortening, mitochondrial dysfunction and oxidative stress or chronic inflammation.
  • These different models all attempt to understand the consequences of ageing, not the causes.


Indeed, rather than focusing on our DNA and trying to protect it to slow down our ageing, what if we protected our proteome?

What is the proteome?

  • Proteins – from the Greek protos meaning “first” – are only exceeded as a constituent of the human body by water, and account for around 20% of its mass.
  • The term was coined by analogy with the genome: the proteome being to proteins what the genome is to genes, i.e.
  • the set of genes/proteins of an individual – this protein set varying according to the activity of the genes.


A structural role: many proteins are central to the maintenance and cohesion of our tissues. For example, actin and tubulin are involved in cell architecture. Keratin is involved in the architecture of our epidermis, hair and nails. Collagen is a protein that plays an important role in the structure of bones, cartilage and skin.
A functional role: enzymatic (for example, proteases are involved in cleaning up dysfunctional proteins and in desquamation), hormonal (for example, insulin regulates glycaemia), transport (for example, aquaporins transport water in the different layers of the skin) or defence (for example, immunoglobulins are involved in the immune response). All vital functions are thus ensured by the activity of proteins.

Carbonylation, the leading cause of irreparable damage to our proteome

  • It is under constant threat, because protein synthesis and degradation also depend on proteins.
  • Over time and as a result of external aggression, the proteome is subjected to various alterations, the most formidable of which is carbonylation, irreversible damage linked to the oxidation of proteins.
  • These carbonylated protein aggregates are found in most age-related diseases, as well as in the main signs of skin ageing.

Antioxidant chaperone molecules to act on the causes of ageing


To correctly perform their many jobs, proteins need to fold into a range of shapes and are helped out by specialised proteins called “chaperones”. These help out the proteins after their synthesis by ribosomes, or their correct folding after stress, such as heat.

  • In short, chaperones (protein or chemical) are the doctors of malformed proteins.
  • At the same time, their antioxidant effectiveness neutralises the causes of carbonylation.
  • In Deinococcus radiodurans, because its proteome is protected against oxidative damage by chaperone molecules, it remains intact and can then able to repair damage to its genome.


Miroslav Radman is founder and scientific director of the Mediterranean Institute for Life Sciences (MedILS). The MedILS has received funding from the NAOS company for several research collaborations. He is a consultant and member of the NAOS Scientific Committee.

Sapient Extends Multi-Omics Services with High Throughput Discovery Proteomics

Retrieved on: 
Dienstag, Februar 6, 2024

Sapient , a biomarker discovery organization providing bespoke services for multi-omics data generation and analysis, has announced the roll-out of its high throughput discovery proteomics services, enabling measure of thousands of proteins in blood and tissue across diverse biological pathways.

Key Points: 
  • Sapient , a biomarker discovery organization providing bespoke services for multi-omics data generation and analysis, has announced the roll-out of its high throughput discovery proteomics services, enabling measure of thousands of proteins in blood and tissue across diverse biological pathways.
  • This offering further extends Sapient’s capabilities for dynamic biomarker discovery, utilizing its state-of-the-art mass spectrometry -based platform, which also powers its discovery metabolomics and lipidomics approaches.
  • “We are particularly excited to extend Sapient’s offerings to include discovery proteomics,” said Jeramie Watrous, PhD, Co-Founder and Head of Analytical R&D at Sapient.
  • More information on Sapient’s high throughput discovery proteomics can be found at: https://sapient.bio/discovery-proteomics-services/

Pixelgen Technologies and Australian Biosearch Announce Distribution Agreement

Retrieved on: 
Dienstag, Februar 6, 2024

STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies® announced today a non-exclusive agreement with leading distributor Australian Biosearch. The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets. 

Key Points: 
  • STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies ® announced today a non-exclusive agreement with leading distributor Australian Biosearch .
  • The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets.
  • "The Australasian biotech market is rapidly growing, and this agreement will help ensure our products reach this important region as we expand globally."
  • Earlier this month, Pixelgen announced a distribution agreement for Japan and launched a sales team in the U.S. with a new global sales position in Boston.